Harman Rebecca M, Marx Charlotte, Van de Walle Gerlinde R
Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States.
Front Cell Dev Biol. 2021 Mar 19;9:654885. doi: 10.3389/fcell.2021.654885. eCollection 2021.
The therapeutic potential of the mesenchymal stromal cell (MSC) secretome, consisting of all molecules secreted by MSCs, is intensively studied. MSCs can be readily isolated, expanded, and manipulated in culture, and few people argue with the ethics of their collection. Despite promising pre-clinical studies, most MSC secretome-based therapies have not been implemented in human medicine, in part because the complexity of bioactive factors secreted by MSCs is not completely understood. In addition, the MSC secretome is variable, influenced by individual donor, tissue source of origin, culture conditions, and passage. An increased understanding of the factors that make up the secretome and the ability to manipulate MSCs to consistently secrete factors of biologic importance will improve MSC therapy. To aid in this goal, we can draw from the wealth of information available on secreted factors from MSC isolated from veterinary species. These translational animal models will inspire efforts to move human MSC secretome therapy from bench to bedside.
间充质基质细胞(MSC)分泌组由MSC分泌的所有分子组成,其治疗潜力正在深入研究。MSC很容易在培养中分离、扩增和操控,而且很少有人对其采集的伦理问题提出异议。尽管临床前研究前景乐观,但大多数基于MSC分泌组的疗法尚未应用于人类医学,部分原因是对MSC分泌的生物活性因子的复杂性尚未完全了解。此外,MSC分泌组是可变的,受个体供体、组织来源、培养条件和传代的影响。对构成分泌组的因素有更多了解,并具备操控MSC持续分泌具有生物学重要性的因子的能力,将改善MSC治疗。为实现这一目标,我们可以借鉴从兽医物种分离的MSC分泌因子的丰富信息。这些转化动物模型将推动人类MSC分泌组疗法从实验室走向临床应用。